Back to UBS Group AG UBS Group AG

KTTAKTTA
10 quarters

Position history for UBS Group AGUBS Group AG's holdings in PASITHEA THERAPEUTICS CORP

Yes. Ubs holds 188,111 shares of KTTA (Pasithea Therapeutics), worth $96,877, as of its Q2 2026 13F filing. It increased the position from 26,149 shares in Q1 2026. Ubs has held KTTA since Q1 2024, across 10 quarterly 13F filings.

Current Value

$96,877

Current Shares

188,111

Total Value Change

+$92,469

Total Shares Change

+187,503

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
188,111
+619.4%
$96,8770.0%$0.52
24
2026-Q1
Increased
26,149
+97.2%
$19,4020.0%$0.74
20
2025-Q4
Decreased
13,263
-27.8%
$17,1090.0%$1.29
0
2025-Q3
Decreased
18,381
-56.4%
$13,4550.0%$0.73
0
2025-Q2
Increased
42,142
+871.7%
$30,3840.0%$0.72
21
2025-Q1
Decreased
4,337
-66.3%
$5,6380.0%$1.30
0
2024-Q4
Increased
12,868
+96.0%
$40,5340.0%$3.15
22
2024-Q3
Increased
6,567
+172x
$35,5930.0%$5.42
22
2024-Q2
Decreased
38
-93.8%
$1920.0%$5.06
0
2024-Q1
New
608
-
$4,4080.0%$7.25
22

Other major holders of KTTA: Janus Henderson Group Ltd., ADAGE CAPITAL PARTNERS GP, L.L.C., AMERIPRISE FINANCIAL INC

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used